Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Clinical Trials Delayed By Poor Reference Safety Information

Executive Summary

EU regulators are increasingly raising objections over the reference safety information that companies include in their clinical trial applications and updated investigator's brochures.

You may also be interested in...



UK MHRA Takes Companies To Task Over Trial Safety Information Reporting

Sponsors of clinical trials in the EU have recently been inundated with objections from regulators for incorrectly managing their clinical trial reference safety information, which in turn has resulted in these trials being significantly delayed. A UK MHRA inspector discusses some of the common issues identified during inspections on this front.

Elusive EU Clinical Trial Rules Slip Again -This Time To Late 2018

The schedule for getting the EU's clinical trial portal and database up and running seems to have slipped again, this time by almost a year compared with earlier estimates. As currently forecast, the new system is not likely to be in place, or the provisions of the new Clinical Trial Regulation (CTR) in effect, until the autumn of 2018.

EMA Aims For Better Info On Benefit-Risk Balance To Support Drug Choices In Pregnancy

The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel